Latest Delcath Systems News & Updates

See the latest news and media coverage for Delcath Systems. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
Delcath Systems

Interventional oncology company focused on liver cancer treatments

delcath.com
Headquarters
New York, United States
Founded year
1987
Company type
Public company
Number of employees
125–200

Last updated

Latest news about Delcath Systems

In short: Delcath Systems achieved profitability in 2025 and projected revenue growth to over $100 million for 2026 following key regulatory and clinical gains.

Company announcements

  • Delcath Systems

    Delcath Systems reports Q1 2026 financial results

    Revenue reaches $25M, up from $19.8M. Issues $100M 2026 guidance. Highlights HEPZATO growth and CHOPIN trial publication.

  • Delcath Systems

    Delcath Systems announces CHEMOSAT inclusion in ESMO–EURACAN guidelines

    CHEMOSAT Hepatic Delivery System for Melphalan is recommended as a liver-directed therapy for uveal melanoma with liver metastases. It supports improved survival from Phase 3 trials.

  • Delcath Systems

    Delcath Systems announces CHOPIN trial publication

    Results in The Lancet Oncology show PHP with immunotherapy improves PFS, OS, and response rates in metastatic uveal melanoma.

  • Delcath Systems

    Delcath Systems reports Q4 and full year 2025 financial results

    Revenue reaches $85.2 million with $2.7 million net income. HEPZATO KIT drives growth; 2026 guidance projects at least $100 million revenue. 28 active centers; 140% procedure volume increase.

Unlock all announcements with a

Media coverage

Unlock all articles with a

Never miss news about Delcath Systems

Track Delcath Systems and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Trending companies

Discover what's making headlines across other trending companies.